Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Alpine Income Property Trust Inc | PINE | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 14.95 | 05:54:21 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 14.95 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 14.25 - 17.76 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 14.95 | USD |
Alpine Income Property Trust Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 203.59M | 13.62M | - | 45.64M | 2.92M | 0.21 | 69.79 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Alpine Income Property News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PINE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.58 | 15.47 | 14.58 | 15.14 | 63,003 | 0.37 | 2.54% |
| 1 Month | 15.35 | 15.56 | 14.325 | 15.12 | 57,612 | -0.40 | -2.61% |
| 3 Months | 15.60 | 16.13 | 14.325 | 15.39 | 55,724 | -0.65 | -4.17% |
| 6 Months | 14.52 | 17.6799 | 14.32 | 15.88 | 57,070 | 0.43 | 2.96% |
| 1 Year | 15.70 | 17.76 | 14.25 | 16.01 | 71,052 | -0.75 | -4.78% |
| 3 Years | 18.27 | 21.069 | 14.25 | 17.69 | 73,139 | -3.32 | -18.17% |
| 5 Years | 19.00 | 21.069 | 7.56 | 17.11 | 69,748 | -4.05 | -21.32% |
Alpine Income Property Description
| Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202. |
